Baijin Life Science Holdings Limited (HKG:1466)

Revenue by Segment

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Jewellery Business	63.57M	115.19M	50.35M	85.23M	59.94M
Skincare Business	25.73M	20.37M	3.33M	-	-
Strategic Investment	-	-	-	1.65M	2.71M
Total	89.30M	135.56M	53.68M	86.88M	62.65M

Revenue by Geography

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
United States of America (USA)	16.85M	68.77M	42.33M	74.48M	53.60M
Hong Kong	46.40M	46.19M	6.79M	8.99M	3.35M
The People's Republic of China (PRC)	25.73M	20.37M	3.33M	538.00K	53.00K
Others	329.00K	224.00K	448.00K	307.00K	1.24M
Other Europe	-	-	780.00K	267.00K	1.45M
United Kingdom (“UK”)	-	-	-	1.69M	2.89M
Other Asia	-	-	-	607.00K	69.00K
Total	89.30M	135.56M	53.68M	86.88M	62.65M

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 2, 2026

Data Sources Report a data error